FibroGen(FGEN) - 2025 Q2 - Quarterly Results

Exhibit 99.1 FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update SAN FRANCISCO, August 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments. "In the second quarter, we continued to make steadfast progress in advancing our clinical pipeline. Trial initiation activities for the Phase 2 monotherapy trial of FG-3246 are progressing, and we expect to start ...